EPS

Amid financial scrutiny and following a major trial failure, Vistagen's upcoming Q3 update is a critical test for its novel pherine pipeline.

MetaVia's drug vanoglipel gets a major boost from AI modeling, validating its potential to treat complex metabolic diseases like MASH and Type 2 Diabetes.

A new study reveals financial firms see big returns from AI but struggle with deployment due to poor data quality and IT complexity, forcing a major rethink.

An expanded partnership aims to deliver a once-daily oral tablet for hypoparathyroidism, potentially revolutionizing treatment for thousands of patients.

Affinia Therapeutics gets the green light for a human trial of AFTX-201, a one-time therapy for a devastating genetic heart disease, BAG3 DCM.

Aethlon Medical's upcoming Q3 report puts its finances under a microscope as investors weigh a tight cash runway against progress on its Hemopurifier device.

Aramark has increased its quarterly dividend, a move reflecting strong financials. But what does it say about its strategy in a changing global market?

New 4-year real-world data shows Zevra's drug stabilizes the rare, fatal 'Childhood Alzheimer's' disease, marking a milestone for patients and families.

The firm's assets grew on market gains, but significant client outflows and shrinking fees triggered a sharp stock drop, revealing key industry pressures.

CDW announces a $0.630 quarterly dividend, marking 12 straight years of increases. Discover how its robust capital strategy fuels consistent investor returns.

Automotive seating giant Adient boosts its 2026 forecast, banking on strong North American production and operational gains, despite a reported net loss.

As Crown Crafts preps its Q3 earnings, investors watch to see if strategic shifts can overcome financial pressures in the competitive juvenile products market.

Atlanticus Holdings Corp. confirms its quarterly preferred stock dividend, highlighting a rare blend of FinTech innovation with reliable investor returns.

With major acquisitions complete, Huntington's leadership will face investors to outline their vision for growth amid a complex economic landscape.

As PHINIA preps for its NYSE Investor Day, it plans to prove its value by balancing legacy engine tech with bold investments in a lower-carbon future.

With a key drug for a rare disease nearing the finish line, Spruce adds two industry veterans to navigate the high-stakes FDA approval process.

As CFO Mike Santomassimo prepares for the UBS conference, investors seek clarity on Wells Fargo's strategy after its asset cap removal and rate cut impacts.

As X4 Pharmaceuticals preps for a key investor summit, all eyes are on its pivotal trial for chronic neutropenia and the commercial fate of XOLREMDI®.

Pharming Group projects strong 2026 growth, fueling ambitious clinical programs for rare immunodeficiencies and mitochondrial diseases.

Facing a sharp drop in 2025 profits and a dividend cut, Finnish asset manager eQ Plc tasks new CEO Jouko Pölönen with a major strategic reboot.